Isabella Ciccone, MPH

Three of 4 patients withdrew from their previous enzyme replacement therapy following treatment with AT845 gene therapy.

As a recap from ACTRIMS 2023, get caught up on some of the latest news in multiple sclerosis as the NeurologyLive® team shares some of our data updates.

A group of experts in the care of patients with rare diseases—Emma Ciafaloni, MD, FAAN; Martina Bebin, MD, MDA; Timothy Miller, MD, PhD; George Small, MD; Bruce Cree, MD, PhD, MAS, FAAN—shared their perspectives on hot topics of treatment and management.

The wearable device received its original FDA go-ahead in 2019, and has since demonstrated effectiveness in preventive and acute care for migraine treatment in adolescents and adults.

In recognition of Rare Disease Day, the NeurologyLive® team offered an extensive update on the state of care and treatment for a few rare neurological diseases, including Pompe disease, Rett syndrome, among others.

A survey showed that 69% of patients with neuromyelitis optica spectrum disorders reported lost income because of hospital visits related to disease relapse.

Results from the open-label SAkuraMoon study show consistent relapse freedom in satralizumab-treated patients with aquaporin-4-IgG-seropositive NMOSD.

A preclinical assessment of evobrutinib showed it demonstrated superior efficacy in targeting compartmentalized neuroinflammation in multiple sclerosis compared with anti-CD20 treatment.

An analysis of patients with MOGAD showed that only 50% of those treated with various immunotherapies over a long-term period maintained relapse-free status.

Secondary findings from a phase 3 study demonstrate a significant decrease in new T1 enhancing lesions and new enlarging hyperintense T2 lesions in patients with multiple sclerosis undergoing glatiramer acetate depot treatment.

Majority of patients with relapsing multiple sclerosis demonstrated achieving and maintaining no evidence disease activity after being treated with ublituximab.

Gregory Day, MD, MSc, MSCI, FAAN, a neurologist at Mayo Clinic in Jacksonville Florida, talked about the current state of treating autoimmune encephalitis and the significance of the ExTINGUISH trial.

In honor of World Encephalitis Day, held February 22, 2023, get caught up on some of the latest news in autoimmune encephalitis as the NeurologyLive® team shares some of our data updates and expert insights.

Researchers designed a new screening tool to assist nonmovement disorders specialists with identifying involuntary movements in patients aged at least 4 years of age with an inborn error of metabolism.

In honor of American Heart Month, held February 2023, get caught up on some of the latest news in stroke as the NeurologyLive® team shares some of our data updates.

Brian Grosberg, MD, and Stephanie Bakaysa, MD, of Hartford HealthCare Medical Group, offered their clinical perspectives on the recently published survey study on management for migraines during pregnancy.

Analysis on the EARLYSTIM trial assessing deep brain stimulation of the subthalamic nucleus in early Parkinson disease showed maintained speech intelligibility and nonspeech oral movements.

As a recap from ISC 2023, get caught up on some of the latest news in stroke as the NeurologyLive® team shares some of our data updates and expert insights.

Frequent medication change, adverse events, and low medication adherence appears more frequently in patients with narcolepsy who use complementary and alternative medicine.

In honor of Duchenne Muscular Dystrophy Awareness Week, held February 13, 2023, to February 19, 2023, get caught up on some of the latest news in Duchenne muscular dystrophy as the NeurologyLive® team shares some of our data updates.

Although the magnitude of the association for smoking, atrial fibrillation and left ventricular hypertrophy did not decrease, their importance for stroke risk likely increases with age.

Data showed improvement in excessive daytime sleepiness and cataplexy frequency for children with narcolepsy on pitolisant.

A meta-analysis displayed a small magnitude of pooled effect estimates for the studied skip-amenable mutation classes in Duchenne muscular dystrophy at 1 year follow up.

Investigators concluded that the therapeutic effectiveness of antiparkinsonian medications is short and limited for intolerable abdominal pain.

In honor of International Epilepsy Day, held February 13, 2023, get caught up on some of the latest news in epilepsy as the NeurologyLive® team shares some of our data updates and expert insights.

Caregivers of patients with advancing PD were more likely to spend more hours caring per day and had a higher self-perceived burden, compared with caregivers for patients with early PD.

Blood pressure medications may not be safe or effective to use for lowering systolic blood pressure following endovascular treatment for acute ischemic stroke.

Patients with noncardioembolic ischemic stroke do not typically monitor post-stroke longterm to detect atrial fibrillation although findings from a trial follow-up suggest otherwise.

Results from a recent study suggest that greater cumulative exposure to estrogen throughout a woman’s lifespan could increase her risk of stroke.

Descartes-08, an investigational autologous RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) has been dosed with the first participant in phase 2b randomized controlled trial.